Emerging reverse transcriptase inhibitors for HIV-1 infection

MA Rai, S Pannek, CJ Fichtenbaum - Expert opinion on emerging …, 2018 - Taylor & Francis
ABSTRACT Introduction: There are 36.7 million people living with HIV with 20.9 million
having access to antiretroviral therapy (ART). Nucleoside/nucleotide reverse transcriptase …

Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors

EL Asahchop, MA Wainberg, RD Sloan… - Antimicrobial agents …, 2012 - Am Soc Microbiol
Highly active antiretroviral therapy (HAART) consists of a combination of drugs to achieve
maximal virological response and reduce the potential for the emergence of antiviral …

Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: the development pipeline and recent clinical data.

ZK Sweeney, K Klumpp - Current opinion in drug discovery & …, 2008 - europepmc.org
Efavirenz non-nucleoside reverse transcriptase inhibitor (NNRTI)-based therapy or boosted
protease inhibitor (PI)-based therapy are currently recommended as first-line regimens for …

Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection

MA Wainberg, JPC Sawyer, JSG Montaner… - Antiviral …, 2005 - journals.sagepub.com
There is a need for new antiretroviral drugs with activity against HIV isolates resistant to
currently available agents and improved short and long-term tolerability profiles. Clinical trial …

Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors

GL Regina, A Coluccia… - Antiviral Chemistry and …, 2010 - journals.sagepub.com
HIV type-1 (HIV-1) non-nucleoside reverse transcriptase inhibitors (NNRTIs) are key drugs
of highly active antiretroviral therapy (HAART) in the clinical management of AIDS/HIV …

Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment

Y Wang, E De Clercq, G Li - Expert opinion on drug metabolism & …, 2019 - Taylor & Francis
Introduction: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are essential
components of highly active antiretroviral therapy against HIV-1 infections. Here, we provide …

[HTML][HTML] Investigational antiretroviral drugs: what is coming down the pipeline

RM Gulick - Topics in Antiviral Medicine, 2018 - ncbi.nlm.nih.gov
Over the past 30 years, antiretroviral drug regimens for treating HIV infection have become
more effective, safer, and more convenient. Despite 31 currently approved drugs, the …

Non-nucleoside reverse transcriptase inhibitors: the NNRTI boom

OS Pedersen, EB Pedersen - Antiviral Chemistry and …, 1999 - journals.sagepub.com
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are promising drugs for the
treatment of HIV when used in combination with other anti-HIV drugs such as nucleoside …

Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms

D Li, P Zhan, E De Clercq, X Liu - Journal of medicinal chemistry, 2012 - ACS Publications
Currently, five NNRTIs have been approved by US Food and Drug Administration (US FDA)
for the clinical treatment of AIDS, ie, nevirapine, delavirdine, efavirenz, etravirine, and …

Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1

J Balzarini - Current topics in medicinal chemistry, 2004 - ingentaconnect.com
Almost fifteen years ago, the first non-nucleoside reverse transcriptase (RT) inhibitor
(NNRTI) lead compounds have been discovered. Nowadays, three NNRTIs are approved for …